Panacea Biotec's Q1 FY 2025-26 Quarterly Results

Result Summary

• Panacea Biotec Ltd reported a 17.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 44.2%.
• Its expenses for the quarter were up by 16.4% QoQ and 27.1% YoY.
• The net profit decreased 299.0% QoQ and decreased 124.9% YoY.
• The earnings per share (EPS) of Panacea Biotec Ltd stood at 0.66 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Panacea Biotec Ltd is a pharmaceutical and biotechnology company. The company is known for its contributions in the development, manufacturing, and commercialization of biopharmaceuticals, vaccines, and pharmaceutical formulations. As a key player in the healthcare sector, Panacea Biotec operates in an industry characterized by rapid innovation and strict regulatory standards. This company has been involved in various collaborations and research initiatives to expand its product offerings and increase its market presence. However, specific recent developments or strategic partnerships are not provided in the current context.

Revenue

In the first quarter of the fiscal year 2026 (Q1FY26), Panacea Biotec Ltd reported a total income of ₹172.37 crores. This represents a significant increase of 17.0% compared to the previous quarter (Q4FY25), where the total income was ₹147.27 crores. On a year-over-year basis, the total income grew by an even more substantial 44.2%, up from ₹119.52 crores in Q1FY25. These figures indicate a robust revenue growth trajectory for the company over both the quarterly and annual periods.

Profitability

Panacea Biotec Ltd experienced a notable turnaround in its profitability metrics during Q1FY26. The company achieved a profit before tax (PBT) of ₹6.56 crores, a significant improvement from the loss of ₹2.12 crores in Q4FY25 and a considerable upswing from the loss of ₹17.05 crores in Q1FY25. The tax expense for Q1FY26 was ₹2.60 crores, compared to a negative tax expense of ₹0.13 crores in the previous quarter and a negative ₹1.17 crores in the same quarter last year. Consequently, the profit after tax (PAT) for Q1FY26 was ₹3.96 crores, a remarkable recovery from the loss of ₹1.99 crores in Q4FY25 and the loss of ₹15.88 crores in Q1FY25. Earnings per share (EPS) reflected this positive shift, standing at ₹0.66 in Q1FY26, compared to a negative ₹0.23 in Q4FY25 and negative ₹2.59 in Q1FY25.

Operating Metrics

Analyzing the operating expenses, Panacea Biotec Ltd's total expenses for Q1FY26 were ₹177.13 crores, marking an increase of 16.4% quarter-over-quarter from ₹152.13 crores in Q4FY25. Year-over-year, total expenses rose by 27.1% from ₹139.31 crores in Q1FY25. Despite the rise in expenses, the company managed to achieve positive net profitability. The operating efficiency, reflected in the profit before tax and profit after tax improvements, suggests a favorable shift in the company's operational dynamics relative to previous quarters. However, specific financial ratios such as the P/E ratio, debt-to-equity ratio, or current ratio are not directly available from the provided data.